Shire rejects £27bn takeover AbbVie bid
Shire rejected AbbVie’s latest £46.11 cash and share proposal arguing it is“fundamentally undervaluing” the company
Friday 20 June 2014
Shire has rejected a trio of possible offers worth up to £27.3 billion from a US suitor after vowing to remain independent.
The company, best-known for its Vyvanse blockbuster treatment for attention deficit hyperactivity disorder, faced the approaches from pharmaceuticals firm AbbVie while AstraZeneca was fending off a £63 billion takeover attempt from Pfizer.
Shire today said it rejected AbbVie’s latest £46.11 cash and share proposal, a 23 per cent premium to last night’s close, as “fundamentally undervaluing” the company.
But the shares leapt 14 per cent, or 522p, to 4260p as investors weighed into company, which has long been seen as a takeover target.
Chairman Susan Kilsby underlined the company’s growth prospects with a new target to double annual product sales, which account for the bulk of revenues, to $10 billion (£5.9 billion) by 2020, and urged shareholders to “take no action”.
She said: “The board believes the proposal fundamentally undervalued Shire and its prospects and that as an independent company Shire’s focused growth strategy will continue to deliver significant shareholder value and patient benefits.”
Shire stressed its 19 per cent rise in product sales growth over the past year, and the strong growth of its rare diseases unit, bolstered by the $4.2 billion deal for US company ViroPharma last year. Shire is building up the division as it faces more generic competitors to its ADHD drugs. “Shire has a long track record of delivering for shareholders and addressing unmet patient needs,” she added.
Panmure Gordon analyst Savvas Neophytou said Shire could be worth as much as £55 a share and noted the “distinct lack of the word ‘final’” anywhere in AbbVie’s announcement despite talks no longer taking place.
He added: “Shire’s rare diseases business is one of the hottest assets in biopharmaceuticals... Given the company’s growth characteristics, a premium valuation is warranted in our view.” The company also highlighted total shareholder returns of 99 per cent over the past year, including reinvested dividends.
Though London listed, Shire is domiciled for tax purposes in Ireland. If successful in the approach AbbVie planned to move its tax base to the UK under an inversion structure to cut its US tax bill, similar to Pfizer’s plans for Astra. Shire’s board also had “concerns regarding the execution risks associated with the proposed inversion structure”.
- 1 Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
- 3 Bill Cosby: Isn’t it obvious why his accusers have stayed silent up until now?
- 4 Halle Berry takes ex-boyfriend Gabriel Aubry to court for allegedly trying to make daughter look less African-American
- 5 Isis propaganda image showing 'abuse of Muslim woman by soldiers' is actually taken from Hungarian porn film
Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
Ferguson decision: Tea Party website mocks Michael Brown's family over T-shirt typo
Michael Brown shooting: Ten things we know – or know better – now the Ferguson grand jury's work is over
Isis propaganda image showing 'abuse of Muslim woman by soldiers' is actually taken from Hungarian porn film
Derren Brown on the disappointment of coming out: 'It’s not that people react badly to it – they really don't care'
Rochester by-election: Ukip gains second MP as Tory defector Mark Reckless holds seat
'Beast of Bolsover' Dennis Skinner takes Ukip MP Mark Reckless to task moments after he is sworn in
Rochester by-election: Labour MP Emily Thornberry resigns after posting white van and England flags tweet
The young are the new poor: Sharp increase in number of under-25s living in poverty, while over-65s are better off than ever
Revealed: How the world gets rich – from privatising British public services
Exclusive: UK approved £7m Israeli arms sales in six months before Gaza conflict
iJobs Money & Business
£Attractive: Citifocus Ltd: High calibre individual with significant product d...
£Negotiable: Citifocus Ltd: Leading global bank seeks experienced credit analy...
£Attractive Package: Citifocus Ltd: High calibre individual with a high degree...
£Attractive: Citifocus Ltd: High calibre individual with superior academics an...